Shire is a biotechnology company that researches, develops, licenses, manufactures, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Shire markets its products through wholesalers, distributors, and various pharmacies.

Employee Rating

3.0More
StateClosed
TypeSubsidiary
Parent CompanyTakeda Pharmaceutical
HQDublin, IE
Founded1986
Websiteshire.com
Shire was founded in 1986 and is headquartered in Dublin, IE

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Shire

Flemming Ornskov

Flemming Ornskov

CEO
Thomas Dittrich

Thomas Dittrich

CFO
Andreas Busch

Andreas Busch

Head of Research and Development and Chief Scientific Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Show more

Shire Office Locations

Shire has offices in Dublin, Bannockburn, Cambridge, Exton and in 48 other locations
Dublin, IE (HQ)
50 Baggot Street Lower
The Rocks, AU
225 George St
Wien, AT
67 Industriestraße
Bruxelles, BE
47 Rue Montoyer
Sofia, BG
2 2a ul. "Saborna"
Toronto, CA
3800 22 Adelaide St W
Show all (64)

Shire Financials and Metrics

Summary Metrics

Founding Date

1986
Shire is a subsidiary of Takeda Pharmaceutical

Shire Revenue

Shire's revenue was reported to be £42.95 m in FY, 2018
Annual
GBPFY, 2016FY, 2017FY, 2018

Revenue

11.4b15.2b43.0m

Revenue growth, %

70%33%

Operating expense total

46.4m5.3b

Depreciation and amortization

1.2b1.8b9.0k
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018Q3, 2018

Revenue

816.2m849.4m874.3m972.2m1.1b1.1b1.2b1.2b1.1b1.2b1.3b1.2b1.3b1.5b1.7b1.7b2.4b3.7b3.9b3.9b

Cost of goods sold

101.9m119.1m112.7m124.5m143.7m166.5m158.4m152.5m167.9m155.9m175.7m197.1m229.5m227.8m248.6m778.1m1.3b1.1b1.1b1.2b

Gross profit

714.3m730.3m761.6m847.7m919.2m919.6m1.0b1.1b932.5m1.0b1.1b1.0b1.1b1.3b1.5b1.7b2.6b2.8b2.7b

Gross profit Margin, %

88%86%87%87%86%85%86%87%85%87%86%84%83%85%85%68%70%72%70%
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

45.7k219.3k17.0k4.0k550.6m620.0m1.5b2.2b3.0b135.5m528.8m472.4m

Accounts Receivable

5.0k4.0k692.5m845.0m824.2m961.2m1.2b2.6b3.0b

Prepaid Expenses

45.1m174.9m221.8m263.0m221.5m197.4m806.3m795.3m

Inventories

260.0m340.1m436.9m455.3m544.8m635.4m3.6b3.3b
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m588.0m865.0m745.4m665.1m3.4b1.3b327.4m4.3b

Depreciation and Amortization

255.5m294.8m308.6m324.4m407.3m637.2m1.5b2.3b

Inventories

(58.2m)(64.4m)(88.2m)(36.6m)(25.3m)(63.2m)(255.8m)(145.1m)

Accounts Payable

25.9m(10.0m)136.7m67.9m5.3m109.2m621.6m
Show all financial metrics

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Approved Phase Products

2 3 4 7
Show all operating metrics

Shire Acquisitions / Subsidiaries

Company NameDateDeal Size
BaxaltaJanuary 11, 2016$32 b
DyaxNovember 02, 2015$5.90 b
Foresight BiotherapeuticsAugust 03, 2015$300 m
Meritage PharmaFebruary 24, 2015$245 m
NPS Pharmaceuticals, Inc.January 11, 2015$5.20 b
Lumena PharmaceuticalsMay 13, 2014$260 m
Fibrotech TherapeuticsMay 02, 2014$75 m
ViroPharma IncorporatedNovember 11, 2013$4.20 b
SARcode BioscienceMarch 25, 2013$160 m
PremacureMarch 12, 2013
Show more

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 26.2% from Hematology, 10.0% from Genetic Diseases, 18.4% from Neuroscience, 30.2% from Immunology, 11.6% from Internal Medicine and 3.6% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Shire Online and Social Media Presence

Embed Graph

Shire News and Updates

A One Korean Painting Now the Trusted Painters Sutherland Shire Serving the Sydney Region

To accomplish painting job weather it is residential or commercial in Sutherland Shire numerous of people trust on A One Korean Painting professional painting services.They literally deliver consistent quality in their work at very affordable rates. read more

Takeda's Shire Deal Drags It Into Unanticipated Operating Loss

Takeda's Shire Deal Drags It Into Unanticipated Operating Loss

Takeda Cuts Profit Forecast on Shire Deal, Lifts Revenue Outlook

Takeda Lowers Annual Profit Forecast by 24% Due to Shire Deal

FTC loses Shire appeal, losing round in fight against citizen petition abuse

An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.

FTC loses Shire appeal, losing round in fight against citizen petition abuse

An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.

Glucagon Like Peptide 2 Receptor Market In-Depth Analysis including key players Hanmi Pharmaceuticals Co Ltd, Naia Ltd, Shire

HTF MI broadcasted a new title “Global Glucagon Like Peptide 2 Receptor Market Insights, Forecast to 2025” Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Shire Frequently Asked Questions

  • When was Shire founded?

    Shire was founded in 1986.

  • Who are Shire key executives?

    Shire's key executives are Flemming Ornskov, Thomas Dittrich and Andreas Busch.

  • What is Shire revenue?

    Latest Shire annual revenue is £43 m.

  • Who are Shire competitors?

    Competitors of Shire include Pfizer, Celgene and Amgen.

  • Where is Shire headquarters?

    Shire headquarters is located at 50 Baggot Street Lower, Dublin.

  • Where are Shire offices?

    Shire has offices in Dublin, Bannockburn, Cambridge, Exton and in 48 other locations.

  • How many offices does Shire have?

    Shire has 64 offices.